IMPACT BIOMEDICAL INC.(IBO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IBO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for IMPACT BIOMEDICAL INC. (IBO), a Healthcare sector company. IBO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), IMPACT BIOMEDICAL INC. reports quarterly revenue of $7.0K, net income of $-2.3M, free cash flow of $-464.0K. Top institutional holders of IBO by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. IBO trades on the NYSE exchange and files with the SEC under CIK 1834105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMPACT BIOMEDICAL INC. directly from SEC EDGAR.
Revenue
Q1 2026
$7.0K
Net Income
Q1 2026
$-2.3M
Free Cash Flow
Q1 2026
$-464.0K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-173.0% YoYOperating Income
-6.3% YoYEPS (Diluted)
-442.9% YoYTotal Assets
-61.0% YoYOp. Cash Flow
+33.7% YoY| Metric | FY 2025 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $32.0K | — | $50.0K |
| Net Income | $-11.8M -173.0% | $-4.3M +40.2% | $-7.3M |
| Operating Income | $-4.3M -6.3% | $-4.0M -18.3% | $-3.4M |
| EPS (Diluted) | $-0.38 -442.9% | $-0.07 -2087.5% | $-0.00 |
| Total Assets | $17.4M -61.0% | $44.6M -4.0% | $46.5M |
| Operating Cash Flow | $-1.9M +33.7% | $-2.9M -27.2% | $-2.2M |
Get alerted when IBO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for IMPACT BIOMEDICAL INC. including:
Top Institutional Holders of IBO
GEODE CAPITAL MANAGEMENT, LLC
$716.2K1,192,925 shVANGUARD CAPITAL MANAGEMENT LLC
$424.9K708,168 shSTATE STREET CORP
$364.7K607,897 shVANGUARD FIDUCIARY TRUST CO
$351.1K585,198 shBlackRock, Inc.
$156.0K259,946 shNORTHERN TRUST CORP
$146.4K243,943 shTWO SIGMA INVESTMENTS, LP
$22.5K37,427 shUBS Group AG
$19.4K32,417 shVanguard Global Advisers, LLC
$19.3K32,201 shMason & Associates Inc
$5.9K10,000 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $716.2K | 1,192,925 |
| VANGUARD CAPITAL MANAGEMENT LLC | $424.9K | 708,168 |
| STATE STREET CORP | $364.7K | 607,897 |
| VANGUARD FIDUCIARY TRUST CO | $351.1K | 585,198 |
| BlackRock, Inc. | $156.0K | 259,946 |
| NORTHERN TRUST CORP | $146.4K | 243,943 |
| TWO SIGMA INVESTMENTS, LP | $22.5K | 37,427 |
| UBS Group AG | $19.4K | 32,417 |
| Vanguard Global Advisers, LLC | $19.3K | 32,201 |
| Mason & Associates Inc | $5.9K | 10,000 |
More Healthcare Companies
View all Healthcare →Put IBO on your watchlist
Track score changes the day IMPACT BIOMEDICAL INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IBO a good stock to buy?
13F Pro's AI-powered analysis of IMPACT BIOMEDICAL INC. (IBO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IBO are available on the IBO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IBO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IBO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMPACT BIOMEDICAL INC.'s investment landscape.